In ₹ Crore except Per Share Latest Annual | NOVARTIND FY25 | BPLPHARMA FY23 | JENBURPH FY26 | KPL FY24 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | — | 37.02× | — | — | 37.02× | |
| Growth | ||||||
| Revenue CAGR 3Y | -2.24% | — | ◆ 7.26% | — | 7.26% -131% | |
| Revenue CAGR 5Y | -6.20% | — | ◆ 9.07% | — | 9.07% -168% | |
| Net Income CAGR 3Y | ◆ 69.01% | — | 12.18% | — | 12.18% +467% | |
| Profitability | ||||||
| EBITDA Margin | ◆ 25.66% | 9.80% | 23.81% | 21.69% | 21.69% +18% | |
| Net Income Margin | ◆ 28.32% | 11.16% | 20.59% | — | 15.88% +78% | |
| Return on Common Equity | ◆ 12.85% | 12.74% | — | — | 12.74% +1% | |
| Return on Capital Employed | 11.07% | — | — | ◆ 19.18% | 19.18% -42% | |
| Return on Assets | 10.65% | 7.90% | ◆ 15.37% | — | 11.63% -8% | |
| Credit & Quality | ||||||
| Total Debt/Equity | ◆ 0.00× | 0.04× | — | 0.43× | 0.23× -100% | |
| Interest Coverage | ◆ 115.88× | 7.10× | — | 4.54× | 5.82× +1891% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹356 Cr | ₹218 Cr | ₹169 Cr | ₹307 Cr | ₹218 Cr +63% | |
| Net Income | ₹101 Cr | ₹24.3 Cr | ₹34.7 Cr | — | ₹29.5 Cr +242% | |
| Total Assets | ₹948 Cr | ₹308 Cr | ₹226 Cr | ₹398 Cr | ₹308 Cr +208% | |
| EPS | — | ₹42.14 | — | — | ₹42.14 | |